- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03612414
Efficacy of a Dietary Supplement (Aqualief®) in Xerostomic Patients (Aqualief)
Effetti Sulla Salivazione a Seguito Della Somministrazione di un Integratore Alimentare (Aqualief®) a Base di Carnosina ed Hibiscus Nei Soggetti Xerostomici: Studio Multicentrico, Randomizzato, in Doppio Cieco, Controllato Verso Placebo
Xerostomia is defined as the subjective complaint of dry mouth. Symptoms of dry mouth may range from mild oral discomfort to significant oral disease that can compromise patients' health, dietary intake and quality of life. Xerostomia is accompanied by numerous signs and symptoms mainly in the mucous membranes, lips, tongue, salivary glands and teeth.
This study was designed to verify efficacy and safety of a novel dietary supplement (Aqualief),designed with the aim of stabilizing the saliva flux and pH at a neutral level and to improve the acid buffering capacity of saliva.
Study Overview
Status
Intervention / Treatment
Detailed Description
Sixty patients with xerostomia (grade 1-2 according to RTOG/EORTC) from different etiologies were recruited at the Clinica Odontoiatrica dell'Università degli studi dell'Insubria (Varese, Italy). Exclusion criteria were subjects under treatment using drugs to treat hyposalivation (e.g. pilocarpine) and xerostomia grade ≥ 3. Patients with severe hyposalivation were excluded (saliva flow rate at baseline <0.1 ml min-1) due to their inability to dissolve the tablet formulation.
Written informed consent was received from all patients before study initiation. The study was conducted in accordance with the principles laid out by the Declaration of Helsinki 1964 and its subsequent amendments and with the International Committee on Harmonization Guidelines for Good Clinical Practice and in compliance with local ethical and legal requirements. The study was approved by the ethics committee at the participating site.
The study was a prospective, randomized, double-blind, placebo-controlled trial undertaken at the Clinica Odontoiatrica dell'Università degli Studi dell'Insubria (Varese, Italy). Eligible patients who had developed xerostomia RTOG/EORTC grade 1-2 were randomized in a 1:1 ratio, with one group receiving three Aqualief tablets (after meals: breakfast, lunch, dinner) daily for 6 days. The second group received a placebo tablet given with the same regimen. The primary objective of the study was to assess the safety and efficacy of Aqualief in stabilizing the saliva pH at a neutral level compared with placebo. The secondary objective was to determine whether Aqualief induced an increase of unstimulated or stimulated saliva and in ameliorating the symptoms related to oral dryness.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Varese, Italy, 21100
- Università degli Studi dell'Insubria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects of both sex
- Age ≥ a 18 years
- Able to understand and sign the Informed Consent, and fill in the patient's diary
- Subjects suffering from Xerosotmia Grade 1-2 (according to RTOG/EORTC scale)
- Sjögren Sindrome
- Lambert-Eaton Sindrome
- Diabetes mellitus and low metabolic control
- Anxiety
- Alcool abuse
- Salivary glands trauma
- Radio and Chemotherapy for head & neck cancer
- Methamphetamine, cannabis, heroin abuse
- Xerostomia caused by (single and concomitant, i.e. Anti-depressive and anxyolitic drugs; Antihistaminic drugs; Decongestive drugs; Antihypertensive drugs; Muscle relaxants; Urinary incontinence drugs; Drugs for Parkinson treatment)
- Subjects affected by paradental pathology diagnosed according to AAOP criteria, PSR 2-3
Exclusion Criteria:
- Contraindication and/or Hypersensitivity to product's components, and in particular carnosine and Hibiscus
- Subjects that are under treatment with products or drugs ( ie pilocarpin) for hypofunctionality of salivary glands
- Subjects with total ablation of salivary glands caused by chemo or radiotherapy
- Use of experimental drugs during 30 days before the enrolment or during the study
- Conditions that can interfere with the study
- Xerostomia grade 3 or higher
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aqualief® tablets
400 mg mucoadhesive tablets; three times per day just
|
Three tablets/day
|
Placebo Comparator: Placebo tablets
400 mg mucoadhesive placebo tablets, three times per day just
|
Three tablets/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Aqualief on salivation
Time Frame: Change from baseline to 6 days of treatment
|
Changes in saliva production is measured (ml)
|
Change from baseline to 6 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Aqualief
Time Frame: Occurrence of Adverse Events over the 6 days of treatment
|
Incidence of Treatment-Emergent Adverse Events
|
Occurrence of Adverse Events over the 6 days of treatment
|
Effect of Aqualief on dry mouth symptoms
Time Frame: Change from baseline to 6 days of treatment
|
Evaluate the effect of treatments dry mouth symptoms trough Dry Mouth Questionnaire (Thomson Questionnaire)
|
Change from baseline to 6 days of treatment
|
Effect of Aqualief on the pH of saliva
Time Frame: Change from baseline to 6 days of treatment
|
Changes of saliva pH is measured
|
Change from baseline to 6 days of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Luca Levrini, Prfo. MD., Università degli Studi dell'Insubria
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Prot.49 May 31st, 2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Aqualief
-
Helsinn Healthcare SALatis S.r.l.TerminatedXerostomia | Mouth Dryness | Hyposalivation | AsialiaItaly